168986-49-0

Basic information

• Product Name: Methyl 4-piperidineacetate
• Synonyms: 2-(1-Methylpiperidin-4-yl)acetate;4-Piperidine acetic acid methyl ester hydrochloride salt;Methyl 4-piperidineacetate hydrochloride salt;Piperidin-4-yl-acetic acid methyl ester hydrochloride salt≥ 97%;METHYL 4-PIPERIDINEACETATE;4-PIPERIDINE ACETIC ACID METHYL ESTER;PIPERIDIN-4-YL-ACETIC ACID METHYL ESTER;Methyl piperidin-4-ylacetate
• CAS NO: 168986-49-0
• Molecular Formula: C₈H₁₅NO₂
• Molecular Weight: 157.21
• Product Categories: Acids and Derivatives;Amines and Anilines;Piperidines, Piperidones, Piperazines;pharmacetical;Organic acids
• Mol File: 168986-49-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 213.1 °C at 760 mmHg
• Flash Point: 82.7 °C
• Appearance: /
• Density: 0.982 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.40±0.10(Predicted)
• CAS DataBase Reference: Methyl 4-piperidineacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-piperidineacetate(168986-49-0)
• EPA Substance Registry System: Methyl 4-piperidineacetate(168986-49-0)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 168986-49-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H15NO2/c1-9-4-2-7(3-5-9)6-8(10)11/h7H,2-6H2,1H3,(H,10,11)/p-1

Upstream product

• 67-56-1 methanol 
• 256411-39-9 tert-butyl 4-(cyanomethyl)piperidine-1-carboxylate 
• 158407-04-6 tert-butyl 4-(bromomethyl)piperidine-1-carboxylate 
• 69719-84-2 4-(bromomethyl)piperidine 
• 29800-89-3 methyl 4-pyridineacetate 
• 28356-58-3 pyridine-4-acetic acid 
• 51052-78-9 4-piperidinylacetic acid 

Downstream Products

• 180181-83-3 {1-[3-(4-Cyano-benzoylamino)-2,2-dimethyl-butyryl]-piperidin-4-yl}-acetic acid methyl ester 
• 208397-07-3 {1-[3-(4-Cyano-benzoylamino)-2,2-dimethyl-hex-5-enoyl]-piperidin-4-yl}-acetic acid methyl ester 
• 208397-08-4 {1-[3-(4-Cyano-benzoylamino)-2,2,5-trimethyl-hexanoyl]-piperidin-4-yl}-acetic acid methyl ester 
• 1025835-93-1 (1-{3-[(4-Cyano-benzoyl)-prop-2-ynyl-amino]-2,2-dimethyl-heptanoyl}-piperidin-4-yl)-acetic acid methyl ester 
• 180181-40-2 {1-[3-(3-Chloro-phenyl)-3-(4-cyano-benzoylamino)-2,2-dimethyl-propionyl]-piperidin-4-yl}-acetic acid methyl ester 
• 754183-67-0 (1-isopropylpiperidin-4-yl)acetic acid 
• 1620075-72-0 C₂₇H₃₁N₃O₄S 

Relevant articles and documents

BROAD SPECTRUM ANTI-CANCER COMPOUNDS

Described herein, inter alia, are compounds for treating cancer and methods of use. This disclosure features chemical entities (e.g., small hairpin RNAs (shRNAs), micro RNA (miRNAs), small interfering RNA (siRNAs), small molecule inhibitors, antisense nucleic acids, peptides, viruses, CRISPR-sgRNAs, or combinations thereof) that inhibit one or more of m6A writers (e.g., methyltransferase like 3 (Mettl3 or MT-A70) or methyltransferase like-14 (Mettl14)), m6Am writers (e.g., phosphorylated CTD interacting factor I (PCIF 1), or Mettl3/14), m6A erasers (e.g., fat-mass and obesity-associated protein (FTO) or ALKB homolog 5 (ALKBH5)), m6Am erasers (e.g., FTO), m6A readers (e.g., YTH domain-containing family proteins (YTHs)), YTF domain family member 1 (YTHDF 1), YTF domain family member 2 (YTHDF 2), YTF domain family member 3 (YTHDF 3), or tyrosine-protein phosphatase non-receptor type 2 (PTPN2).

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents

C9-Substituted phenanthrene-based tylophorine derivatives (PBTs) (13-36) were synthesized and evaluated as in vitro anticancer agents against the human A549 lung cancer cell line. Twelve active compounds were further examined against DU-145 (prostate), ZR-751 (breast), KB (nasopharyngeal), and KB-Vin (multidrug resistant KB subline) human cancer cell lines. They showed potent cytotoxic activity against both wild type and matched multidrug resistant KB cell lines, and displayed notable selectivity toward DU-145 (prostate) and ZR-751 (breast) cancer cell lines. The mode of action of this class may be distinctly different from that of other cancer chemotherapeutic compounds. Three PBT analogs were also evaluated in a murine model. Compound 24b showed modest in vivo antitumor activity against human A549 xenograft in nude mice as well as potent in vitro cytotoxic activity, and thus, is a promising anticancer lead compound.